Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor

Clin Transl Med. 2024 Jun;14(6):e1691. doi: 10.1002/ctm2.1691.

Authors

Zi-Yang Shi¹, Ying Fang¹, Peng-Peng Xu¹, Hong-Mei Yi², Jian-Feng Li¹, Yan Dong¹, Yue Zhu¹, Meng-Ke Liu¹, Di Fu¹, Shuo Wang¹, Qing Shi¹, Rong Shen¹, Hui-Juan Zhong¹, Chao-Fu Wang², Shu Cheng¹, Li Wang^{1

3}, Feng Liu¹, Wei-Li Zhao^{1

3}

Affiliations

¹ Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Department of Pathology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
³ Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China.

No abstract available

Publication types

Letter

MeSH terms

Histone Deacetylase Inhibitors* / pharmacology
Histone Deacetylase Inhibitors* / therapeutic use
Humans
Lymphoma / drug therapy
Lymphoma / genetics
Lymphoma / metabolism
Proto-Oncogene Proteins c-bcl-2* / genetics
Proto-Oncogene Proteins c-bcl-2* / metabolism
Proto-Oncogene Proteins c-myc / genetics
Proto-Oncogene Proteins c-myc / metabolism

Substances

BCL2 protein, human
Histone Deacetylase Inhibitors
MYC protein, human
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-myc

Grants and funding